Keala Milles, Contributing Author at MarketBeat

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

These stocks fell last year, which helped boost their dividends. Now around $10 a share each, they offer great value, but could also have more risk.

Tesla announced price cuts on popular models in order to boost sales, after several earnings misses. Hopefull this can build momentum to restore stock value

Despite a positive preliminary earnings report, Tmobile stock is slipping. This article investigates some of the factors that may be contributing to the dip.

Pepsi introduced a new lemon-lime beverage, "Starry" to somewhat poor reception, but that does not seem to affect long-term growth.

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

After the announcement in July, the Amazon acquisition of One Medical is complete. What does this deal mean for healthcare or tech investors?

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023

Premier Inc, Patterson Companies, Inc, and Walgreens Boots Alliance, Inc are three healthcare stocks consistently paying decent-to-great dividends

Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.

Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.

Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate.

These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.

VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.

Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum

Dexcom is relying on the interest and sales of its new continuous glucose monitor--which recently received FDA approval--to boost revenue (and stock value).

Revenue loss and a recent sell-off confirm that Cano Health stock may be struggling right now but a membership-focused strategy could help them recover.

How do Costco Wholesale and Amazon.com compare at the end of the year, and does this information affect their moderate buy ratings?

Discount retailers can be strong stock investments as their share price is often more appealing though they are not always reliable

Christmas time tends to be big for retailers, which can make them good bets for investors. Here are three moderate buy stocks as we approach year's end.

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

Okta is struggling but a recent earnings beat has boosted expectations. Can they maintain this momentum and get out of the red?

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

The cloud computing industry appears to be slowing but many stocks in the sector are a moderate buy. This means long term outlook is positive.

Rambus Inc grew quickly since its ipo but slipped lately. Rebounds tend to grow further, though, so analysts think it could continue this trend

Salesforce, climbing out of a rough spot, still may not make the best short-term investment. In the future, it could make a big move.

Cisco Systems has expanded operations and expect revenue to grow but have recently announced a restructuring plan that could help.

Without the ability to turn significant profits, Alibaba is struggling. Fortunately, the industry as a whole is facing challenges, so watch the sector closely.

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

Costco has had strong earnings and analysts project the growth will continue but comparable data shows this may be consistent across the industry

Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.

Penny stocks are cheap, but risky because they can shift quickly and in big ways. Here are two penny stocks making moves up and one heading down.

Vision Hydrogen Corporation decalred 2-for-1 split and changed their name to Vision Energy; Along with their green energy projects, this should entice investors

DraftKings share price continues to slip, even with a revenue beat and fewer losses than expected, and analysts have rated the stock a moderate Buy.

DoorDash has not done too well since its IPO but in a couple years, sales have improved greatly. Don't let sluggish earnings deter you from a potential buy.

Twilio's financials suggest uncertainty but analysts believe a rebound may be coming soon, as they give it a HOLD rating.

AMD is down but this could be the start of another rebound as sales and earnings show promise in the long term, particularly when compared against competitors.

Analysts believe Paypal could be a Strong Buy as earnings are not only steady but growing, even amid tough competition; thanks to resilient sales.

Apple could have better long-term promise than its peers and industry thanks to strong earnings and a new revenue strategy.

TTD may not always have the best numbers but they consistently outpace their competitors and have excellent guidance for the next quarter and full-year.

ExxonMobil stock started the year strong and growth may beat others in the black gold industry. Analysts have given ExxonMobil a "moderate buy" rating

New subscriptions have helped raise NFLX guidance, but extreme volatility keep analyst to a conservative HOLD rating, awaiting the next earnings report.

NextEra Energy may not always have better numbers than competitors, but steady growth and an impressive upside could make it a worthy investment.

Analysts seem to agree that steady and stable growth coupled with a potentially best-selling T2D medication makes LLY a STRONG BUY

Despite a small pandemic hiccup, Kraft Heinz shows great solid earnings and strong momentum promise. But is it a portfolio-worthy consumer staples heavy hitter?

APA Corporation stock holds strong while other energy companies struggle. Is the a safer and more affordable option than competitors?

General Motors' consistent earnings beats compared to the rest of the industry coupled with strong outlook makes it tempting for investors.